# Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids

> **NCT01324934** · PHASE3 · TERMINATED · sponsor: **Neovii Biotech** · enrollment: 40 (actual)

## Conditions studied

- Renal Transplant Rejection

## Interventions

- **DRUG:** ATG-Fresenius S

## Key facts

- **NCT ID:** NCT01324934
- **Lead sponsor:** Neovii Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-10
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Recruitment became very slow.
- **Last updated:** 2015-05-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01324934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01324934, "Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01324934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*